remimazolam
Sign in to saveAlso known as CNS-7056
Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults for invasive diagnostic or surgical procedures lasting 30 minutes or less. It is a benzodiazepine drug, developed by PAION AG in collaboration with several regional licensees as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in the induction of anesthesia and conscious sedation for minor invasive procedures.
Key facts
- Drug.CAS_number
- 308242-62-8
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 451607085
- Drug.image
- Remimazolam.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 222
- Drug.tradename
- Byfavo
- Drug.DailyMedID
- Remimazolam
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- N05
- Drug.ATC_suffix
- CD14
- Drug.legal_CA
- Schedule IV
- Drug.legal_DE
- Anlage III
- Drug.legal_UK
- PSA
- Drug.legal_US
- Schedule IV
- Drug.legal_EU
- Rx-only
- Drug.elimination_half life
- 45–70 minutes
via Wikipedia infobox
Wikidata facts
- Mass
- 438.069138
Show 4 more facts
- chemical formula
- C₂₁H₁₉BrN₄O₂
- isomeric SMILES
- CC1=CN2C3=C(C=C(C=C3)Br)C(=N[C@H](C2=N1)CCC(=O)OC)C4=CC=CC=N4
- canonical SMILES
- CC1=CN2C3=C(C=C(C=C3)Br)C(=NC(C2=N1)CCC(=O)OC)C4=CC=CC=N4
- Commons category
- Remimazolam
Sources (1)
via Wikidata · CC0
~4 min read
Article
7 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- Research
- References
- External links
Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults for invasive diagnostic or surgical procedures lasting 30 minutes or less. It is a benzodiazepine drug, developed by PAION AG in collaboration with several regional licensees as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in the induction of anesthesia and conscious sedation for minor invasive procedures.
Remimazolam was found to have both a more rapid onset and a shorter duration than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.